Announcement on Obtaining Approval for Two New Indications of Innovative Drug HSK44459 Ointment

Haisco Pharmaceutical Group Co., Ltd.·May 26, 2026·3 pages

✨ AI Summary

The company has received approval from the National Medical Products Administration for clinical trials of two new indications for the innovative drug HSK44459 ointment, targeting psoriasis and atopic dermatitis. This approval follows a review confirming compliance with drug registration requirements. HSK44459 is a novel treatment with promising efficacy and safety profiles, aimed at addressing the current lack of effective therapies for these conditions.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Securities Code: 002653
Securities Abbreviation: Haikang
Announcement Number: 2026-055

Announcement on Obtaining Approval for Two New Indications of Innovative Drug HSK44459 Ointment

Haikang Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") has recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The relevant information is announced as follows:

Drug Name Dosage Form Application Matter Indication Acceptance Number HSK44459 Ointment Domestic production drug registration clinical trial Psoriasis CXHL2600299 Atopic Dermatitis CXHL2600300 CXHL2600301 CXHL2600302 CXHL2600303 CXHL2600304

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.